Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov-Dec;10(8):878-882.
doi: 10.6004/jadpro.2019.10.8.9. Epub 2019 Nov 1.

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Amber C King  1 , Jennifer S Orozco  1
Affiliations

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Amber C King et al. J Adv Pract Oncol. 2019 Nov-Dec.

Abstract

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies. The immune activation that confers the efficacy of axi-cel comes at the price of potentially devastating adverse phenomena: cytokine release syndrome and neurotoxicity. This article serves as an overview of axi-cel, including a review of the available clinical evidence, mechanism of action, and management of some of the unique toxicities of axi-cel.

PubMed Disclaimer

Conflict of interest statement

Dr. King has served on an advisory board for Genentech. Dr. Orozco has no potential conflicts of interest to disclose.

References

    1. Chaganti S., Illidge T., Barrington S., Mckay P., Linton K., Cwynarski K.,…British Committee for Standards in Haematology (2016). Guidelines for the management of diffuse large B-cell lymphoma. British Journal of Haematology, 174(1), 43–56. 10.1111/bjh.14136 - DOI - PubMed
    1. Genentech, Inc (2018). Actemra (tocilizumab) package insert. Retrieved from https://www.gene.com/download/pdf/actemra_prescribing.pdf
    1. Jackson H. J., Rafiq S., & Brentjens R. J. (2016). Driving CAR T-cells forward. Nature Reviews Clinical Oncology, 13(6), 370–383. 10.1038/nrclinonc.2016.36 - DOI - PMC - PubMed
    1. Kite Pharma, Inc (2018). Yescarta (axicabtagene ciloleucel) package insert. Retrieved from https://www.fda.gov/downloads/UCM581226.pdf
    1. Kochenderfer J. N., Dudley M. E., Kassim S. H., Somerville R. P. T., Carpenter R. O., Stetler-Stevenson M.,Rosenberg S. A. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33(6), 540–549. 10.1200/JCO.2014.56.2025 - DOI - PMC - PubMed

LinkOut - more resources